🇺🇸 FDA

Company profile · Sponsor

Teva

Teva Pharma GmbH

TEVA · NYSE pharma TEL AVIV, EU
Pipeline
24
Drugs
12
Patents
8

Quick answer

Teva (TEVA) is a pharma company. headquartered in TEL AVIV, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 12 drugs, and 8 patents to this profile..

Company facts

Ticker TEVA
Exchange NYSE
Company type pharma
Headquarters TEL AVIV, EU
SEC CIK 0000818686

Pipeline (24)

Search pipeline →

  1. ACR16

    Teva

    Huntington's Disease

    phase 3 small molecule completed

    1 trial

  2. ACTIQ (Oral transmucosal fentanyl citrate)

    Teva

    Breakthrough Pain

    phase 3 small molecule completed

    1 trial

  3. Albuterol

    Teva

    Asthma

    phase 3 small molecule completed

    2 trials

  4. Albuterol MDPI

    Teva

    Asthma

    phase 3 small molecule completed

    1 trial

  5. Albuterol Spiromax

    Teva

    Exercise-Induced Bronchoconstriction (EIB)

    phase 3 small molecule completed

    1 trial

  6. Albuterol Spiromax®

    Teva

    Asthma

    phase 3 small molecule completed

    4 trials

  7. Albuterol Sulfate

    Teva

    Asthma

    phase 3 small molecule completed

    1 trial

  8. Albuterol sulfate (ABS)

    Teva

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  9. Armodafinil

    Teva

    Depression

    phase 3 small molecule completed

    4 trials

  10. Armodafinil

    Teva

    Traumatic Brain Injury

    phase 3 small molecule terminated

    2 trials

  11. Armodafinil

    Teva

    Excessive Daytime Sleepiness

    phase 3 small molecule completed

    1 trial

  12. Armodafinil

    Teva

    Narcolepsy

    phase 3 small molecule completed

    2 trials

  13. Armodafinil 100 to 250 mg/day

    Teva

    Excessive Daytime Sleepiness

    phase 3 small molecule completed

    1 trial

  14. Armodafinil 150 mg/day

    Teva

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  15. Armodafinil 150 mg/day

    Teva

    Excessive Sleepiness

    phase 3 small molecule completed

    1 trial

  16. Armodafinil 250 mg/day

    Teva

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  17. Arsenic trioxide

    Teva

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  18. Arsenic trioxide

    Teva

    Acute Promyelocytic Leukemia

    phase 3 small molecule completed

    1 trial

  19. Azelastine hydrochloride and Fluticasone propionate

    Teva

    Seasonal Allergic Rhinitis

    phase 3 small molecule active

    1 trial

  20. BDP

    Teva

    Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  21. BDP HFA

    Teva

    Seasonal Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  22. BDP Nasal Aerosol

    Teva

    Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  23. Balugrastim

    Teva

    Chemotherapy-induced Neutropenia

    phase 3 mab completed

    1 trial

  24. Beclomethasone Dipropionate 640

    Teva

    Persistent Asthma

    phase 3 small molecule completed

    1 trial

Drugs (12)

Search drugs →

  1. abacavir sulfate

    ABACAVIR SULFATE

    ORAL approved

  2. acamprosate calcium

    ACAMPROSATE CALCIUM

    ORAL approved

  3. acetaminophen

    BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

    RECTAL approved

  4. acetazolamide

    ACETAZOLAMIDE

    ORAL approved

  5. acetazolamide sodium

    ACETAZOLAMIDE SODIUM

    INJECTION approved

  6. acetohexamide

    DYMELOR

    ORAL approved

  7. acitretin

    SORIATANE

    ORAL approved

  8. acyclovir sodium

    ACYCLOVIR SODIUM

    INJECTION approved

  9. albuterol

    ALBUTEROL

    INHALATION approved

  10. alendronate sodium

    ALENDRONATE SODIUM

    ORAL approved

  11. almotriptan malate

    ALMOTRIPTAN MALATE

    ORAL approved

  12. alvimopan

    ALVIMOPAN

    ORAL approved

Patents (8)

Search patents →

  1. US 12310929

    Use of rasagiline for the treatment of restless legs syndrome

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12258401

    Anti-CD47 combination therapy

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12157729

    Solid state forms of Belumosudil and Belumosudil salts

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12139528

    Treating refractory migraine

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12091388

    Solid state forms of Reproxalap

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11826322

    Pre-filled syringe

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11813359

    Sustained release olanzapine formulations

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11773083

    Solid state forms of Belumosudil and Belumosudil salts

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Teva?

Teva (TEVA) is a pharma company. headquartered in TEL AVIV, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 12 drugs, and 8 patents to this profile..

What pipeline programs does Teva sponsor?

We track 24 ClinicalTrials.gov-linked programs for Teva, including ACR16 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Teva company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.